These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 26985289)
1. Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains. Taylor AM; Vaswani RG; Gehling VS; Hewitt MC; Leblanc Y; Audia JE; Bellon S; Cummings RT; Côté A; Harmange JC; Jayaram H; Joshi S; Lora JM; Mertz JA; Neiss A; Pardo E; Nasveschuk CG; Poy F; Sandy P; Setser JW; Sims RJ; Tang Y; Albrecht BK ACS Med Chem Lett; 2016 Feb; 7(2):145-50. PubMed ID: 26985289 [TBL] [Abstract][Full Text] [Related]
2. Discovery of Benzo[ Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032 [TBL] [Abstract][Full Text] [Related]
3. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. Divakaran A; Talluri SK; Ayoub AM; Mishra NK; Cui H; Widen JC; Berndt N; Zhu JY; Carlson AS; Topczewski JJ; Schonbrunn EK; Harki DA; Pomerantz WCK J Med Chem; 2018 Oct; 61(20):9316-9334. PubMed ID: 30253095 [TBL] [Abstract][Full Text] [Related]
4. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries. Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791 [TBL] [Abstract][Full Text] [Related]
5. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). Zhang M; Zhang Y; Song M; Xue X; Wang J; Wang C; Zhang C; Li C; Xiang Q; Zou L; Wu X; Wu C; Dong B; Xue W; Zhou Y; Chen H; Wu D; Ding K; Xu Y J Med Chem; 2018 Apr; 61(7):3037-3058. PubMed ID: 29566488 [TBL] [Abstract][Full Text] [Related]
6. Design and Optimization of Benzopiperazines as Potent Inhibitors of BET Bromodomains. Millan DS; Kayser-Bricker KJ; Martin MW; Talbot AC; Schiller SER; Herbertz T; Williams GL; Luke GP; Hubbs S; Alvarez Morales MA; Cardillo D; Troccolo P; Mendes RL; McKinnon C ACS Med Chem Lett; 2017 Aug; 8(8):847-852. PubMed ID: 28835800 [TBL] [Abstract][Full Text] [Related]
7. Bromodomains: Structure, function and pharmacology of inhibition. Ferri E; Petosa C; McKenna CE Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650 [TBL] [Abstract][Full Text] [Related]
9. Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping. Zhang Z; Gu L; Wang B; Huang W; Zhang Y; Ma Z; Zeng S; Shen Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):808-817. PubMed ID: 30879350 [TBL] [Abstract][Full Text] [Related]
10. Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay. Chen Z; Zhang H; Liu S; Xie Y; Jiang H; Lu W; Xu H; Yue L; Zhang Y; Ding H; Zheng M; Yu K; Chen K; Jiang H; Luo C Medchemcomm; 2017 Jun; 8(6):1322-1331. PubMed ID: 30108844 [TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors. Sharp PP; Garnier JM; Hatfaludi T; Xu Z; Segal D; Jarman KE; Jousset H; Garnham A; Feutrill JT; Cuzzupe A; Hall P; Taylor S; Walkley CR; Tyler D; Dawson MA; Czabotar P; Wilks AF; Glaser S; Huang DCS; Burns CJ ACS Med Chem Lett; 2017 Dec; 8(12):1298-1303. PubMed ID: 29259751 [TBL] [Abstract][Full Text] [Related]
12. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma. Markman RL; Webber LP; Nascimento Filho CHV; Reis LA; Vargas PA; Lopes MA; Zanella V; Martins MD; Squarize CH; Castilho RM Cell Oncol (Dordr); 2019 Apr; 42(2):143-155. PubMed ID: 30539410 [TBL] [Abstract][Full Text] [Related]
13. Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors. Wang L; Pratt JK; Soltwedel T; Sheppard GS; Fidanze SD; Liu D; Hasvold LA; Mantei RA; Holms JH; McClellan WJ; Wendt MD; Wada C; Frey R; Hansen TM; Hubbard R; Park CH; Li L; Magoc TJ; Albert DH; Lin X; Warder SE; Kovar P; Huang X; Wilcox D; Wang R; Rajaraman G; Petros AM; Hutchins CW; Panchal SC; Sun C; Elmore SW; Shen Y; Kati WM; McDaniel KF J Med Chem; 2017 May; 60(9):3828-3850. PubMed ID: 28368119 [TBL] [Abstract][Full Text] [Related]
14. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Taniguchi Y Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996 [TBL] [Abstract][Full Text] [Related]
15. Targeting BET bromodomains for cancer treatment. Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433 [TBL] [Abstract][Full Text] [Related]
16. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. Nadeem A; Al-Harbi NO; Al-Harbi MM; El-Sherbeeny AM; Ahmad SF; Siddiqui N; Ansari MA; Zoheir KM; Attia SM; Al-Hosaini KA; Al-Sharary SD Pharmacol Res; 2015 Sep; 99():248-57. PubMed ID: 26149470 [TBL] [Abstract][Full Text] [Related]
17. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. Zhao Y; Zhou B; Bai L; Liu L; Yang CY; Meagher JL; Stuckey JA; McEachern D; Przybranowski S; Wang M; Ran X; Aguilar A; Hu Y; Kampf JW; Li X; Zhao T; Li S; Wen B; Sun D; Wang S J Med Chem; 2018 Jul; 61(14):6110-6120. PubMed ID: 30015487 [TBL] [Abstract][Full Text] [Related]
18. Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups. Hu J; Wang Y; Li Y; Cao D; Xu L; Song S; Damaneh MS; Li J; Chen Y; Wang X; Chen L; Shen J; Miao Z; Xiong B Eur J Med Chem; 2018 Apr; 150():156-175. PubMed ID: 29525435 [TBL] [Abstract][Full Text] [Related]
19. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490 [TBL] [Abstract][Full Text] [Related]
20. Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor. Sperandio D; Aktoudianakis V; Babaoglu K; Chen X; Elbel K; Chin G; Corkey B; Du J; Jiang B; Kobayashi T; Mackman R; Martinez R; Yang H; Zablocki J; Kusam S; Jordan K; Webb H; Bates JG; Lad L; Mish M; Niedziela-Majka A; Metobo S; Sapre A; Hung M; Jin D; Fung W; Kan E; Eisenberg G; Larson N; Newby ZER; Lansdon E; Tay C; Neve RM; Shevick SL; Breckenridge DG Bioorg Med Chem; 2019 Feb; 27(3):457-469. PubMed ID: 30606676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]